ASCO: Daraxonrasib Effective for Metastatic Pancreatic Ductal Adenocarcinoma

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, Senior Medical Editor, B. Pharm. Last updated on June 1, 2026.

via HealthDay

MONDAY, June 1, 2026 -- Daraxonrasib is effective for patients with RAS-mutant and other metastatic pancreatic ductal adenocarcinomas (mPDACs), according to a study presented at the annual meeting of the American Society of Clinical Oncology, held from May 29 to June 2 in Chicago.

Brian Wolpin, M.D., M.P.H., from the Dana-Farber Cancer Institute in Boston, and colleagues conducted a randomized, open-label, phase 3 study involving patients with previously treated mPDAC. Patients were randomly assigned to receive daraxonrasib or chemotherapy (248 and 252 patients, respectively); most had tumors with a RAS G12 variant (228 and 231 in the daraxonrasib and chemotherapy groups, respectively).

The researchers found that in the RAS G12 and the overall population, there were clinically meaningful improvements in the daraxonrasib versus the chemotherapy group for overall survival (median overall survival, 13.2 versus 6.6 months in the RAS G12 subgroup and 13.2 versus 6.7 months in the overall population) and progression-free survival (median progression-free survival, 7.3 versus 3.5 months and 7.2 versus 3.6 months, respectively). The objective response rate was 33.2 and 31.6 percent for participants in the daraxonrasib group among those with a RAS G12 variant and the overall population, respectively, compared with 11.8 and 11.2 percent, respectively, among those in the chemotherapy group. Fewer side effects were seen for those receiving daraxonrasib, with grade 3 or higher adverse events occurring in 43.6 percent, compared to 57.5 percent in the chemotherapy groups.

"The RASolute 302 trial was designed to assess a RAS(ON) multi-selective inhibitor as a second-line treatment for patients with metastatic pancreatic cancer, looking to define a new standard of care for these patients that works better and has less side effects than currently available chemotherapies," Wolpin said in a statement.

Several authors disclosed ties to biopharmaceutical companies, including Revolution Medicines, which is developing daraxonrasib and funded the study.

Press Release

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-06-02 00:30

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords